Affimed (NASDAQ:AFMD) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Affimed (NASDAQ:AFMD) in a research report report published on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Affimed Stock Performance

NASDAQ AFMD opened at $0.83 on Friday. Affimed has a twelve month low of $0.52 and a twelve month high of $8.95. The business’s fifty day moving average is $0.83 and its 200 day moving average is $1.57. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Northern Trust Corp bought a new stake in Affimed during the 4th quarter worth approximately $218,000. Intellectus Partners LLC lifted its holdings in shares of Affimed by 34.0% during the fourth quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 32,053 shares during the period. Finally, Jane Street Group LLC bought a new stake in shares of Affimed in the third quarter worth $44,000. Institutional investors own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.